Trial · NCT01942694
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Development of Diabetes | Approximately 48 months | New-onset diabetes was based on annual glycemic testing of fasting plasma glucose, glycated hemoglobin, and 2-hour post-load plasma glucose and semiannual testing of fasting plasma glucose and glycated hemoglobin. If two or three of the glycemic measures met the 2010 ADA thresholds for diabetes, the participant was considered to have met the diabetes outcome. When only the measure for fasting plasma glucose or glycated hemoglobin met the threshold, confirmatory testing was performed for the positive measure within 8 weeks. If only the measure for 2-hour post-load plasma glucose met the threshold, then a 75-g oral glucose tolerance test to reassess all three glycemic measures was repeated. If the repeat measure was positive or both fasting plasma glucose and glycated hemoglobin were positive (in the case of a repeat oral glucose tolerance test), than the participant was considered to have met the diabetes outcome. |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: 25OHD Concentration | Approximately 48 months | |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Race (as a Proxy for Skin Pigmentation) | Approximately 48 months | Race and ethnic group were reporting by the participant. The category "other" includes American Indian or Alaska Native; Native Hawaiian or other Pacific Islander; and other race. Ethnic group includes any race. |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Pre-diabetes Criteria (Two vs. Three Criteria) | Approximately 48 months | Participants met at least two of three glycemic criteria for prediabetes: fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to 6.9 mmol per liter); plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter) (impaired glucose tolerance); and glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mmol per mole). |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: BMI | Approximately 48 months | |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Waist Circumference | Approximately 48 months | |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Age | Approximately 48 months | |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Geographic Location (as a Proxy for Sun Exposure) | Approximately 48 months | |
| Secondary | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Calcium Intake From Supplements | Approximately 48 months | |
| Secondary | Blood Plasma 25OHD Concentration. | Approximately 48 months | |
| Secondary | Number of Participants With Adverse Events. | Approximately 48 months | |
| Secondary | Change in Blood Pressure as a Continuous Variable. | Approximately 48 months | |
| Secondary | Number of Participants Who Discontinue Study Pills. | Approximately 48 months | |
| Secondary | Change in FPG as a Continuous Variable. | Every 12 months for approximately 48 months | |
| Secondary | Change in 2hPG as a Continuous Variable. | Every 12 months for approximately 48 months. | |
| Secondary | Change in HbA1c as a Continuous Variable. | Every 6 months for approximately 48 months | |
| Secondary | Measurement of Insulin Resistance (Derived From the OGTT). | Every 12 months for approximately 48 months | |
| Secondary | Measurement of Beta Cell Secretion (Derived From the OGTT) | Every 12 months for approximately 48 months | |
| Secondary | Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration. | Every 12 months for approximately 48 months | |
| Other | Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Sex | Approximately 48 months. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01942694/registered